InvestorLens

APRE — APREA THERAPEUTICS INC

Public company

Sign in to save1 tracked investor reported this
For educational research only.InvestorLens analyzes public regulatory filings (SEC EDGAR, STOCK Act PTRs) that may be delayed by 45 days or more. Information shown is historical and is not financial, legal, or tax advice, nor a recommendation or solicitation to buy or sell any security. Always do your own research.

InvestorLens aggregates public filing data to show which tracked investors reported holdings in this stock. Dollar values represent reported position values, not market capitalization, and may be delayed up to 45 days. Not a recommendation.

Sourced from SEC EDGAR public filings

Why are billionaires buying APRE?

Built from public SEC filings and public economic data. Not a recommendation.

Confidence
95
Institutional Conviction
Net accumulation · 1 buying vs 0 selling last quarter
60
Macro Tailwind
Macro conditions are mixed for this sector
55
Why? — Evidence & Confidence ▾

Of 1 tracked investors who changed their APRE position last quarter, 1 bought and 0 sold (100% buy-side). Macro conditions are mixed for this sector (Macro Tailwind 55/100 in a Squeeze regime).

Supporting evidence
  • +1 tracked investor added or increased positions last quarter (Ken Griffin)
  • +1 tracked investors reported holding APRE at their latest filing
  • +Macro Health is 55/100 in a Squeeze regime — historically acceptable for this sectorsource
Contradicting evidence — always shown
  • −13F data is disclosed up to 45 days after quarter end — positions may have changed since
Know the limits
  • · 13F disclosure lag (up to 45 days)
  • · Tracked investors are a sample, not the whole market
  • · Sector regime fit is a historical average, not a guarantee

Every InvestorLens score shows its evidence — including what argues against it. Model conviction-v1 · generated 8/20/2026.

About APREA THERAPEUTICS INC (APRE)

APREA THERAPEUTICS INC (APRE) appears in the most recent 13F filings of 1 tracked institutional investor. The largest disclosed position is held by Ken Griffin (Citadel Advisors), valued at $61,369. Across recent filings, tracked investors recorded 2 new positions, 0 increased, 0 reduced, and 1 exited. All data sourced from SEC 13F filings.

Smart Money Consensus™

Based on recent institutional activity in APRE

67
/100
Institutional Accumulation
Added / Increased2
Reduced0
Exited1
BearishBullish
Crowded Trade Score™

How many top investors track APRE

7
/100
Undiscovered
1investor

Only 1 tracked investor report this position.

UndiscoveredCrowded
151015+

APRE Ownership Composition

How APREA THERAPEUTICS INC is held across tracked investor types, based on reported 13F positions.

Dominant Type
Multi-Strategy / Quant
100% of tracked value
Institutions
1
tracked investors
Total Reported
$47K
combined 13F value
Types1
  • Multi-Strategy / Quant100.0%
Multi-Strategy / Quant(1)
100.0%

Tracked investors currently reporting APRE

  • Ken GriffinJun 30, 2026
    Citadel Advisors
    Shares
    58.6K
    Value
    $47K
    % Portfolio
    0.00%

Recent activity

Frequently asked questions

How many institutional investors hold APRE?
1 tracked institutional investor disclosed a position in APRE (APREA THERAPEUTICS INC) in their most recent 13F filing.
Who is the largest institutional holder of APRE?
Ken Griffin, Citadel Advisors, holds the largest disclosed position in APRE, valued at $61,369.
Did institutional ownership of APRE increase or decrease?
Across recent 13F filings, tracked investors recorded 2 new positions, 0 increased, 0 reduced, and 1 fully exited APRE.
Where does this APRE ownership data come from?
SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.